Jagadish Ashwin, Notta Shahnawaz, Bakeler Stephen, Joseph David
James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA.
James H. Quillen Veterans Affairs Medical Center, Johnson City, TN, USA.
J Pharm Technol. 2025 Jun 14:87551225251348838. doi: 10.1177/87551225251348838.
Pioglitazone is a medication that can be utilized in the management of type 2 diabetes mellitus (T2DM). It can be associated with adverse effects such as edema, weight gain, and heart failure. It is not commonly associated with pleural effusions. Our case involves an 81-year-old man with T2DM who presented to the emergency department due to progressively worsening lower extremity edema and exertional dyspnea. These symptoms began after the patient started to regularly take pioglitazone. He had a large pleural effusion and diffuse anasarca. Pioglitazone was discontinued and he underwent successful thoracentesis and diuresis. The Naranjo scale yielded a score of 7 points, indicating a probable association between pioglitazone and our patient's presentation. There is limited documentation of pleural effusions associated with pioglitazone. Our case is unique as the patient had pleural effusions and anasarca associated with pioglitazone.
吡格列酮是一种可用于治疗2型糖尿病(T2DM)的药物。它可能会引起诸如水肿、体重增加和心力衰竭等不良反应。它通常与胸腔积液无关。我们的病例涉及一名81岁的T2DM男性患者,他因下肢水肿逐渐加重和劳力性呼吸困难而到急诊科就诊。这些症状在患者开始规律服用吡格列酮后出现。他有大量胸腔积液和全身性水肿。停用了吡格列酮,他接受了成功的胸腔穿刺术和利尿治疗。Naranjo量表评分为7分,表明吡格列酮与我们患者的表现之间可能存在关联。与吡格列酮相关的胸腔积液的文献记载有限。我们的病例很独特,因为患者出现了与吡格列酮相关的胸腔积液和全身性水肿。